Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma

Table 2 Biomedical and pathology comparison of most recent studies in ovarian cancer PDX models

		Ricci et al. (2014) [35]	Weroha et al. (2014) [13]	Dobbin et al. (2014) [20]	Topp et al. (2014) [22]	Current study
No. cases		34	168	34	12	9
Tumor types		All EOC types	All EOC types	All EOC types	High-grade serous	High-grade serous
Implantation site	SQ	Yes	No	Yes	Yes	Yes
	IP	Yes	Yes	Yes	No	No
	IB	Yes	No	No	Yes	Yes
Take rate (%)		25	74	85.3 (SC), 22.2 (IP)	83	>90
Passage time (weeks)	Average	Not mentioned	Not mentioned	10 weeks	Not mentioned	6–12 weeks
Passage attempts		P1->6	P1	P1-6	P1	P1-4
Stem cell analysis		No	No	ALDH1, CD44,CD133	No	ALDH1, CD44,CD133
Histology comparison		Yes	Yes	No	No	Yes
Immunohistochemistry analysis	ER/PR	No	No	No	Yes	Yes
Immunohistochemistry analysis	KI67	No	Yes	Yes	Yes	Yes
Mutation analysis	P53	Yes	No	No	Yes	Yes
Gene profile	P0	Yes	Yes	No	No	Yes
Gene profile	P1-x	Yes	P1	No	No	P2

ISSN: 1756-8722